Anti-PD-L1 and anti-PD-1 antibodies are now applied in the treatment of metastatic melanoma, non-small-cell lung cancer (NSCLC), and renal cell carcinoma (RCC), with average objective response rates of 35–40%, 20%, and 25%, respectively [92]. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.